Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home 2024
Archives
Risk factors for cannabis use in young people
With cannabis use among young people on the rise, Ronan Fleury, Prof Bobby Smyth and Prof Mary Cannon. discuss the mental and physical impacts and the importance of understanding the risk factors.
From selfish silo to collaborative culture – embracing data-enabled cancer research
Aedin Culhane and Mark Lawler, Co-Leads of the eHealth Hub for Cancer, reflect on their data-enabled cancer research journeys, how their collaborative team science approach has reaped significant dividends in cancer research and policy and how the hub is inducing a paradigm shift in how health data are deployed on the island of Ireland.
What imaging reveals about engineered endosymbionts
Ashley V. Makela and Christopher H. Contag from the Institute for Quantitative Health Science and Engineering, walk us through watching living therapeutics in action, including what imaging reveals about engineered endosymbionts.
Prolonged lactation: Preventing obesity since infancy
Dr Vincent Prevot and Professors Markus Schwaninger and Ruben Nogueiras explain the significance of the perinatal maternal lifestyle, specifically prolonged lactation, in shielding offspring from chronic disease.
Protein kinases for combating inflammatory disease
Julie Blaising, Discovery Project Leader in Immunology at F. Hoffmann-La Roche Ltd, tells us why protein kinases are an effective target for treating many chronic inflammatory disorders.
AI-empowered neural processing for intelligent human-machine interface and biomedical devices
Jie Gu, Associate Professor from Northwestern University, examines AI-empowered neural processing for intelligent human-machine interface and biomedical devices.
Symptomatic vs. Disease-modifying treatments in neurological diseases: Where next?
An optimal drug for chronic neurological disease would slow down disease progression in the long term, with short-term symptomatic benefits. This would shorten clinical development timelines and reduce the cost and risk level for drug developers. Henri Huttunen Chief Scientific Officer (CSO) at Herantis Pharma Plc explains.
BRAV3 Project: Cardiac regenerative medicine
Prof Felipe Prósper, Head of Department, and Dr Manuel Mazo, from the University of Navarra & Clínica Universidad de Navarra, shares his expertise in cardiovascular diseases, focusing on the work of the BRAV3 project, which includes research in cardiac regenerative medicine.
National sepsis strategy to improve knowledge, prevention and treatment
Discover what you need to know about sepsis from a top group of experts, including their call for a national sepsis strategy to improve its knowledge, prevention, and treatment to save lives.
Treatment of migraines: Minimally invasive surgery, regenerative approach and botox
Giorgio Pietramaggiori and Saja Scherer, MD, from the Global Medical Institute, describe a revolution in the treatment of migraines: minimally invasive surgery, a regenerative approach and Botox.
Personalized cancer medicines
Dr. Priya Hays, PhD, CEO and Science Writer at Hays Documentation Specialists, LLC, guides us through the world of personalized cancer medicines.
Getting leptospirosis onto the lists of neglected tropical diseases
Leptospirosis is a globally important infectious disease, but neglected to the extent that it’s not on WHO’s or FDA’s neglected tropical diseases lists; this needs to change.
Recruiting retired specialists back into part-time practice via telemedicine
Richard J. Santen, MD, Emeritus Professor of Medicine at the University of Virginia in Charlottesville, Virginia, U.S., looks at how to recruit retired specialists to practice part-time via telemedicine.
How the “tides” have turned in pharma manufacturing
Two seasoned experts from CPI, Medicines Manufacturing Innovation Centre, detail how the “tides” have turned in pharma manufacturing.
T cells successfully fighting cancer
Else Marit Inderberg and Sébastien Wälchli from Oslo University Hospital explore what we need to know about T cells successfully fighting cancer.
Asbestos-induced autoantibodies across Libby demographics
Aiden Niblett, Jean Pfau, and Kinta Serve focus on asbestos-induced autoantibodies across different demographics in Libby. They emphasize the importance of understanding the impact of asbestos.
Learning from the COVID-19 Pandemic: Next-generation universal vaccines and immunotherapeutic research
With the COVID-19 pandemic behind us, we need to focus on universal vaccines and/or immunotherapeutic strategies and technologies to tackle ongoing endemic infections with SARS-CoV2, influenza, and RSV and prepare for any future pandemics, says Dr Babita Agrawal.
Cigarette smoking focus: A modeling approach for estimating the impact of health programs
Theodore R. Holford from Yale University charts a modeling approach for estimating the impact of health programs in this cigarette smoking research focus.
Arc: A new target for treating alzheimer’s disease
Antonius M. VanDongen, Associate Professor from Duke University, walks us through Arc, a new target for treating Alzheimer’s disease.
Treating neuropathic pain and nicotine dependence: Epibatidine derivatives as potential therapeutics
Lance R. McMahon, Ph.D. and Jenny L. Wilkerson, Ph.D. from Texas Tech University Health Sciences Center, describe the search for the magic bullet to treat both neuropathic pain and nicotine dependence using novel epibatidine derivatives as potential therapeutics.
